The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells
暂无分享,去创建一个
H. Vrolijk | D. Tscharke | M. Ressing | R. Wolterbeek | M. Heemskerk | J. Wiegant | M. Griffioen | G. Adema | E. Wiertz | L. Hutt-Fletcher | R. Lebbink | C. Büll | R. Hoeben | A. Comvalius | M. Lindenbergh | A. M. Gram | Timo Oosenbrug | Kathryn J. I. Dickson | Marthe F. S. Lindenbergh
[1] A. Rickinson,et al. The immunology of Epstein-Barr virus-induced disease. , 2015, Annual review of immunology.
[2] M. Ressing,et al. Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion. , 2015, The Journal of general virology.
[3] C. Figdor,et al. Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. , 2015, ACS nano.
[4] M. Rowe,et al. Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8+ T Cell Recognition across All Three Phases of the Lytic Cycle , 2014, PLoS pathogens.
[5] G. Adema,et al. Sweet escape: sialic acids in tumor immune evasion. , 2014, Biochimica et biophysica acta.
[6] Michael T. McManus,et al. A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation , 2014, Nature Communications.
[7] Vincenzo Cerundolo,et al. Biology of CD1- and MR1-restricted T cells. , 2014, Annual review of immunology.
[8] G. Adema,et al. Targeting Aberrant Sialylation in Cancer Cells Using a Fluorinated Sialic Acid Analog Impairs Adhesion, Migration, and In Vivo Tumor Growth , 2013, Molecular Cancer Therapeutics.
[9] Jeffrey E. Lee,et al. The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion , 2013, PLoS pathogens.
[10] M. Ressing,et al. EBV BILF1 Evolved To Downregulate Cell Surface Display of a Wide Range of HLA Class I Molecules through Their Cytoplasmic Tail , 2013, The Journal of Immunology.
[11] R. D. de Groot,et al. Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-A , 2012, PloS one.
[12] W. Britt,et al. Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing Antibodies , 2012, PLoS pathogens.
[13] M. Ressing,et al. Hiding Lipid Presentation: Viral Interference with CD1d-Restricted Invariant Natural Killer T (iNKT) Cell Activation , 2012, Viruses.
[14] Stuart M Haslam,et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. , 2012, Nature chemical biology.
[15] J. Mast,et al. Antibody Evasion by a Gammaherpesvirus O-Glycan Shield , 2011, PLoS pathogens.
[16] Hong Thanh Pham,et al. Herpes Simplex Virus 1 Glycoprotein B and US3 Collaborate To Inhibit CD1d Antigen Presentation and NKT Cell Function , 2011, Journal of Virology.
[17] M. Ressing,et al. Viral evasion of T cell immunity: ancient mechanisms offering new applications. , 2011, Current opinion in immunology.
[18] M. Rowe,et al. The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways , 2010, Journal of Virology.
[19] A. Porgador,et al. Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting , 2010, The Journal of Immunology.
[20] P. Bates,et al. Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein , 2010, PLoS pathogens.
[21] R. Dwek,et al. Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. , 2010, Rapid communications in mass spectrometry : RCM.
[22] M. Ressing,et al. The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation , 2009, PLoS pathogens.
[23] M. Ressing,et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates , 2007, The Journal of experimental medicine.
[24] A. Moosmann,et al. Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy , 2007, PloS one.
[25] Laurentiu Spiridon,et al. An N-Linked Glycan Modulates the Interaction between the CD1d Heavy Chain and β2-Microglobulin* , 2006, Journal of Biological Chemistry.
[26] F. Rieux-Laucat,et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome , 2006, Nature.
[27] M. Ressing,et al. Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection1 , 2005, The Journal of Immunology.
[28] P. Stevenson,et al. Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein. , 2005, The Journal of general virology.
[29] A. Fischer,et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product , 2005, The Journal of experimental medicine.
[30] T. Schumacher,et al. Interference with T cell receptor–HLA-DR interactions by Epstein–Barr virus gp42 results in reduced T helper cell recognition , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Schlag,et al. Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. , 2001, Cancer research.
[32] A. Chott,et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells,B cells and monocytes , 2000, Immunology.
[33] J. Neefjes,et al. Recycling MHC class I molecules and endosomal peptide loading. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] L. Hutt-Fletcher,et al. Epstein-Barr Virus Recombinant Lacking Expression of Glycoprotein gp150 Infects B Cells Normally but Is Enhanced for Infection of Epithelial Cells , 1998, Journal of Virology.
[35] R. Gerardy-Schahn,et al. Mutants of the CMP-sialic Acid Transporter Causing the Lec2 Phenotype* , 1998, The Journal of Biological Chemistry.
[36] A. Morgan,et al. The Epstein-Barr virus open reading frame BDLF3 codes for a 100-150 kDa glycoprotein. , 1995, The Journal of general virology.
[37] E. Kieff,et al. A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame. , 1995, Virology.
[38] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[39] M. Epstein,et al. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.
[40] M. Ressing,et al. Immune Evasion by Epstein-Barr Virus. , 2015, Current topics in microbiology and immunology.
[41] Mark M. Davis,et al. The interdisciplinary science of T-cell recognition. , 2013, Advances in immunology.